Ypsomed targets growth with first production facility in the USA

(CONNECT) The medtech firm Ypsomed has started the process of establishing its first production location in the USA. According to a press release, Ypsomed is acquiring an existing building with a footprint of 15,000 square meters that offers future expansion possibilities. The site, which is located in Holly Springs in Wake County in the US State of North Carolina, is expected to commence operations by the end of 2027, with the aim of facilitating future international growth. With an investment of 200 million Swiss francs in the first phase of the project, the company is reportedly keen to move closer to its customers and supply local markets directly.

“The cooperative approach of the local authorities, the excellent infrastructure, and the proximity to top-tier universities provide ideal conditions for our future growth”, as CEO Simon Michel explains in the press release, adding that: “This environment will allow us to attract the skilled workforce we need and to further strengthen our position as a leading supplier of self-injection systems worldwide, while contributing to the security of supply for the US healthcare market”.

According to the press release, the region is regarded as a hub for globally leading biotechnology companies. For example, more than 650 life sciences companies are said to be based in North Carolina’s research triangle alone. These cover every step of the biopharmaceutical supply chain, from research and product development to device manufacturing, all the way through to fill/finish and delivery. In the words of Sean Mayefskie, the mayor of the town of Holly Springs, Ypsomed will be providing urgently needed devices that will “contribute to the creation of life-saving medications”.

Ypsomed supplies injection systems such as pens and auto-injectors for subcutaneous self-medication to pharmaceutical enterprises. According to the information, the first expansion phase will create around 100 new jobs, with long-term plans envisaging growth in the workforce to 200 employees. ce/heg